FDA meeting on September 20-21, 2016

Posted in Latest News on September 23, 2016.

pharmacy-pic2

On September 20-21, 2016 Allison Dudley, Executive Director and David Flynn, Counsel to the Board attended an inter-governmental working meeting at the Food and Drug Administration to discuss the oversight of drug compounding and the relationship between the activities of the FDA and the states. The meeting provided an opportunity to discuss each state’s regulatory framework, recent FDA guidance documents, changes to the FDA’s inspection procedures, and information sharing challenges and opportunities.



More Latest News

Bills That Go Into Effect January 1, 2017
February 17, 2017

SB 0422 Relating to Health Insurance Coverage For Opioids Health Insurance Coverage For Opioids; Providing that a health insurance policy that covers abuse-deterrent opioid analgesic drug products may impose a prior authorization requirement for an abuse-deterrent opioid analgesic drug product … Continue reading


DEA’s suspension of McKesson Corporation Retraction
January 19, 2017

Please see updated information about the DEA’s suspension of McKesson Corporation and controlled substances Continue reading